XML 59 R46.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Investment in Altira (Details) - USD ($) |  |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Dec. 07, 2020 | May 13, 2020 | Dec. 31, 2020 | Jul. 31, 2022 | Jul. 31, 2021 | Jul. 31, 2020
Investment in Altira (Details) [Line Items] |  |  |  |  |  |
Percentage of membership interest |  |  |  | 33.333% |  |
Cost of investments |  |  |  | $ 7,000,000 |  |
Impairment charges |  |  |  |  | $ 7,000,000 |
Membership interest |  |  | 33.00% |  |  |
Business Combination [Member] |  |  |  |  |  |
Investment in Altira (Details) [Line Items] |  |  |  |  |  |
Investment in acquired description | On December 7, 2020, the Company purchased an additional 33.333% of membership interests in Altira, pursuant to a Membership Interest Purchase Agreement (the “Second Altira Agreement”) between the Company and another Altira member, (the “Second Seller”). With this transaction, the Company now owns a right to an aggregate 66.666% of the membership interests in Altira. Pursuant to the Second Altira Agreement, on December 7, 2020, the Second Seller sold his economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive an additional 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Cornerstone Pharmaceuticals) on sales of certain Cornerstone Pharmaceuticals products. The consideration for the purchase of the Membership Interest consists of 1) $1,000,000 that was payable monthly in four equal monthly installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 payable on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Cornerstone Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Cornerstone Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. |  |  |  |  |
Altira [Member] |  |  |  |  |  |
Investment in Altira (Details) [Line Items] |  |  |  |  |  |
Percentage of membership interest |  |  |  | 33.333% |  |
Cost of investments |  |  |  | $ 4,000,000 |  |
Contingent consideration |  |  |  | $ 6,000,000 |  |
Impairment charge |  |  |  |  |  | $ 4,000,000
Purchase Agreement [Member] |  |  |  |  |  |
Investment in Altira (Details) [Line Items] |  |  |  |  |  |
Purchase agreement, description |  | Pursuant to the Purchase Agreement, on May 13, 2020, the First Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Cornerstone Pharmaceuticals) on sales of certain Cornerstone Pharmaceuticals products. The purchase consideration for the purchase of the membership interest consisted of 1) $1,000,000 that was payable monthly in four equal monthly installments of $250,000 each; 2) $3,000,000 payable on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Cornerstone Pharmaceuticals’ Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Cornerstone Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made to the First Seller, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the ten-day average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof. |  |  |  |
Purchase Agreement [Member] | Class B Common Stock [Member] |  |  |  |  |  |
Investment in Altira (Details) [Line Items] |  |  |  |  |  |
Issuance of shares (in Shares) |  |  |  |  | 129,620 |
First Seller [Member] | Class B Common Stock [Member] |  |  |  |  |  |
Investment in Altira (Details) [Line Items] |  |  |  |  |  |
Issuance of value |  |  |  |  | $ 3,500,000 |
Altira Second Seller [Member] | Class B Common Stock [Member] |  |  |  |  |  |
Investment in Altira (Details) [Line Items] |  |  |  |  |  |
Issuance of shares (in Shares) |  |  |  |  | 150,703 |
Issuance of value |  |  |  |  | $ 5,000,000 |
Cash payments |  |  |  |  | $ 2,000,000 |

X
- Definition Impairment charge. + References No definition available. + Details
Name: | rfl_ImpairmentCharge
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Impairment charge. + References No definition available. + Details
Name: | rfl_ImpairmentCharges
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | rfl_InvestmentinAltiraDetailsLineItems
Namespace Prefix: | rfl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of membership interest. + References No definition available. + Details
Name: | rfl_MembershipInterest
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of membership interest. + References No definition available. + Details
Name: | rfl_MembershipInterestPercentage
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Purchase agreement, description. + References No definition available. + Details
Name: | rfl_PurchaseAgreementDescription
Namespace Prefix: | rfl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of receivable acquired in business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationAcquiredReceivablesDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of decreases to the indemnification asset due to cash payments received relating to loss sharing agreements with the Federal Deposit Insurance Corporation (FDIC). + References No definition available. + Details
Name: | us-gaap_FDICIndemnificationAssetCashPaymentsReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.1(h)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910 + Details
Name: | us-gaap_Investments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rfl_BusinessCombinationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rfl_AltiraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=rfl_PurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=rfl_FirstSellerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_AltiraSecondSellerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |